United Therapeutics Executive Sells Shares Under Pre-Arranged Plan
1 report, 1 independent
Updated Oct 17
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Paul A. Mahon assumed the role of EVP and General Counsel at United Therapeutics on October 17, 2026. Separately, the company reported that Mahon sold 8,300 shares on October 15, 2026, after exercising 8,300 stock options. The sale was executed under a Rule 10b5-1 trading plan that was established on August 11, 2025.
From themarketsdaily.com
Why it matters
The sale involved approximately $4.52 million in total, which accounted for about 15.5% of Mahon's pre-trade holding. The filing indicates that the transaction was tied to a same-day option exercise, and Mahon retained a meaningful equity stake and option exposure after the disposition.
From themarketsdaily.com
Who's involved
- United TherapeuticsBiotech company where the executive holds a leadership role
- Martine RothblattCEO and Chairperson of United Therapeutics
Keep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States